06:12 AM EST, 12/04/2024 (MT Newswires) -- Illumina ( ILMN ) has been granted access to Synaffix's patented metal-free click chemistry technology for the development of antibody drugs, Synaffix said Wednesday.

Illumina ( ILMN ) will use the licensed technology for some of its next-generation sequencing products, Synaffix said.

Financial details of the licensing agreement were not disclosed.